Weak First Half, Firmer Order Book
hVIVO (LSE:HVO), the clinical trials services company best known for human challenge trials, reported a sharp fall in first-half revenue but a much larger order book. Interim results published on 15 September 2026, covering the six months to 30 June, showed revenue of £16.3m against £24.2m a year earlier and a swing to an adjusted EBITDA loss. At the same time, the contracted order book more than doubled, and management guided to a substantially firmer second half. Chief executive Yamin "Mo" Khan said the period saw a clear improvement in commercial momentum.
What the Company Does
hVIVO runs human challenge studies, in which volunteers are deliberately exposed to a pathogen under controlled conditions to test vaccines and antivirals. It operates from London and also offers laboratory, early-phase clinical and patient recruitment services. The group now trades under a single hVIVO brand across four service lines, a change intended to present a more joined-up offer to pharmaceutical and biotech sponsors.
Latest Developments
The order book rose to £65m from £30m at the end of 2025. Including the newly acquired CRS Berlin, the group order book stands at £72m. In August 2026 hVIVO bought CRS Berlin, adding Phase I and II capability in dermatology and women's health, for an initial €25,000 plus 18% of annual revenue for 2026 to 2028, subject to a minimum revenue threshold.
Contract wins include a Phase III human challenge trial of a whooping cough vaccine for ILiAD Biotechnologies, described as its largest challenge contract to date, and two further influenza challenge trial contracts, including one with Traws Pharma. Proposal volumes were up about 45% year on year. Chief financial officer Stephen Pinkerton retired on 30 September 2026, with non-executive director Richard Cotton stepping in as interim CFO.
Financial and Dividend Picture
The adjusted EBITDA loss was £4.5m, compared with positive EBITDA before one-off items of £3.0m in the first half of 2025. The statutory loss widened to £6.5m from £0.2m. The company blamed the decline on second-half weighting and the timing of revenue on certain client programmes. Cash was £13.0m at 30 June, down from £14.3m at the end of December. No dividend was paid in the period.
Sector and Index Context
hVIVO is one of the better-known healthcare services businesses in the FTSE AIM All Share Index. Outsourced clinical trial providers have faced weaker demand as biotech funding tightened and some sponsors deferred trials. Human challenge studies remain a niche, but they can speed up vaccine and antiviral development, and hVIVO is among a small number of specialist providers worldwide. Demand for respiratory disease studies tends to be lumpy and linked to sponsor funding cycles.
Key Risks
The full-year outcome depends heavily on the second half, as management expects revenue to roughly double compared with the first. Project deferrals have already pushed some work into 2027 and 2028, and further delays would affect results. Integrating CRS Berlin and handling a change of finance director add execution risk. The business is also exposed to the financial health of small biotech clients.
What to Watch Next
hVIVO expects FY2026 revenue of about £47m, positive adjusted EBITDA in the second half and a low single-digit adjusted EBITDA loss for the year. A January trading update would be the next likely checkpoint. Investors will watch conversion of the enlarged order book, the timing of the ILiAD study, contribution from CRS Berlin and any permanent CFO appointment.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...